Key result
Venous thromboembolism occurs in 7 to 13% of lung cancer patients, with risk factors categorized into patient, tumor, and treatment-related factors, alongside biomarkers like D-dimer.
VTE is a significant cause of morbidity and mortality in lung cancer patients, with incidence rates reaching 7-13%.
No takes yet. Share an insight, caveat, or question.
VTE burden in lung cancer warrants clinical vigilance; leaves open refined risk stratification and prophylaxis trials.
Ay et al. (2016) conducted a review in Lung cancer and venous thromboembolism. Risk factors for VTE was evaluated on Venous thromboembolism (VTE). Venous thromboembolism occurs in 7 to 13% of lung cancer patients, with risk factors categorized into patient, tumor, and treatment-related factors, alongside biomarkers like D-dimer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: